ProQR Therapeutics (PRQR) Given Coverage Optimism Rating of 0.13

Share on StockTwits

Press coverage about ProQR Therapeutics (NASDAQ:PRQR) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ProQR Therapeutics earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 49.3555511417147 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

PRQR has been the subject of a number of recent research reports. HC Wainwright set a $20.00 price objective on ProQR Therapeutics and gave the company a “buy” rating in a research note on Thursday. Zacks Investment Research upgraded ProQR Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a research note on Thursday. Finally, ValuEngine upgraded ProQR Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 23rd. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $12.90.

Shares of NASDAQ PRQR remained flat at $$7.35 during trading on Friday. The company’s stock had a trading volume of 41,514 shares, compared to its average volume of 59,096. ProQR Therapeutics has a twelve month low of $2.75 and a twelve month high of $7.75. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.02 and a quick ratio of 5.64. The stock has a market cap of $234.17 million, a price-to-earnings ratio of -3.79 and a beta of 0.55.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.15. sell-side analysts expect that ProQR Therapeutics will post -1.58 earnings per share for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Featured Article: Average Daily Trade Volume – ADTV

Insider Buying and Selling by Quarter for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply